Nutcracker Therapeutics

From Wikitia
Jump to navigation Jump to search
Nutcracker Therapeutics
IndustryBiotechnology
Founded2018
Headquarters
Emeryville, CA
,
United State
Website[// ] 

Nutcracker Therapeutics is a biotechnology company based in Emeryville, CA that develops mRNA-based oncology therapeutics using a proprietary microfluidics-based manufacturing technology.[1][2]. The technology, similar to "lab-on-a-chip" technology, uses single-use microfluidics biochips that encompass RNA molecule design, drug delivery, and biomanufacturing, and can efficiently produce small volumes of therapeutic mRNA in accordance to Good manufacturing practice (GMP)[2][3][4][5].

The company was founded in 2018 by Igor Khandros, Ph.D., and Benjamin Eldridge[5]. Khandros currently serves as chief executive officer, with Eldridge as chief technology officer[3].

NTX-250, Nutcracker’s lead candidate, is a multimodal RNA therapeutic primarily for use against the HPV-driven cervical cancer precursor, cervical intraepithelial neoplasia[6][7]. The therapeutic contains three RNA molecules: a molecule intended to elicit T cell response against HPV proteins E6 and E7, and two immunostimulatory RNA molecules that boost the therapeutic effect[5][6]. As of 2023, NTX-250 is in the preclinical stage of development.

In November 2022, Nutcracker released preclinical data on NTX-250, at the Society for Immunotherapy of Cancer (SITC) conference, which detailed how the mRNA drug led to tumor-free survival in all ten treated mice[5][8][9]. It also presented data at the American Association for Cancer Research (AACR) Annual Meeting in 2023, including two presentations detailing how the insertion of an endolysosomal trafficking domain into the design of NTX-250 improved immunogenicity[10] and a comparison of delivering the drug locally in the tumor versus intramuscularly[11].

Also during the 2023 AACR Annual Meeting, the research groups of Dr. Lawrence Fong and Dr. David Oh at the University of California, San Francisco presented a study, conducted in collaboration with Nutcracker, that mapped shared tumor antigen reactivity in prostate cancer patients using nanoparticle-encapsulated mRNA, which can be used to inform future prostate cancer vaccine development[12]

References

  1. ↑ Sullivan, Josh (March 14, 2022). "GMP-in-a-box company with Bob Nelsen backing lands $167M to develop its own cancer drugs". Endpoints News. Retrieved December 5, 2023.
  2. ↑ 2.0 2.1 Sheridan, Cormac (2022-08-01). "mRNA printers kick-start personalized medicines for all". Nature Biotechnology. 40 (8): 1160–1162. doi:10.1038/s41587-022-01430-y. ISSN 1546-1696.
  3. ↑ 3.0 3.1 Lynn, Jessica (2022-08-24). "Nutcracker Therapeutics Creating RNA Therapies". Patient Worthy. Retrieved 2023-12-11.
  4. ↑ Pillar, Matthew (July 3, 2023). "Why RNA Is Good For Business". www.bioprocessonline.com. Retrieved 2023-12-11.
  5. ↑ 5.0 5.1 5.2 5.3 Golovin, Danielle; Writer, Staff. "Nutcracker: RNA design, delivery and manufacturing under one roof". BioCentury. Retrieved 2023-12-11.
  6. ↑ 6.0 6.1 Shaffer, Catherine (July 27, 2022). "Nutcracker Therapeutics Aims to Beat HPV-Driven Cancers With Multimodal mRNA Therapeutics". Precision Medicine Online. Retrieved December 1, 2023.
  7. ↑ Gormley, Brian (2023-04-26). "RNA Medicines Startup Orbital Therapeutics Collects $270 Million". Wall Street Journal. ISSN 0099-9660. Retrieved 2023-12-11.
  8. ↑ Haabeth, Ole; DaSilva, Diane; McKinlay, Colin; Liu, Weiqun; Lemmens, Edward; Rae, Christopher; Sallets, Adrienne; Frimannsson, Daniel; Nath, Sangeeta; Peck, Nicole; Li, Ou; Fay, Nicole; Prins, Ruben; Leong, Meredith; Kast, W. Martin (November 7, 2022). "1084 NTX-0250, a multimodal mRNA-based immunotherapy, eradicates large established tumors in a stringent mouse model of HPV16-driven cancer". Journal for ImmunoTherapy of Cancer. BMJ Publishing Group Ltd. 10 (Suppl 2): A1124. doi:10.1136/jitc-2022-SITC2022.1084.
  9. ↑ Cornall, Jim (2022-11-14). "Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy". Labiotech.eu. Retrieved 2023-12-11.
  10. ↑ Liu, Weiqun; Fernandez, Daniel; McKinlay, Colin J.; Frimannsson, Daniel O.; Leong, Meredith L.; Kast, W. Martin; Deutsch, Samuel; Haabeth, Ole Audun W. (April 4, 2023). "Abstract 690: Modification of mRNA-encoded HPV16 antigens to include endolysosomal trafficking domains drives cross-presentation and results in superior in vivo and ex vivo antigen-specific responses". aacrjournals.org. Retrieved December 1, 2023.
  11. ↑ Liu, Weiqun; Da Silva, Diane M.; Lemmens, Edward E.; Colin J., McKinlay; Nath, Sangeeta; Meredith L., Leong; Samuel, Deutsch; Kast, W. Martin; Haabeth, Ole Audun W. (April 4, 2023). "Abstract 5163: Local delivery of mRNA immunotherapy encoding HPV16 antigen, IL-12, and LIGHT/TNFSF14 results in superior immunogenicity and tumor clearance in a murine model of HPV16-driven cancer". aacrjournals.org. Retrieved December 1, 2023.
  12. ↑ Montauti, Elena; Haabeth, Ole; Rae, Chris; Deutsch, Samuel; Fong, Lawrence; Oh, David (April 14, 2023). "Abstract LB346: Mapping of shared tumor antigen reactivity with nanoparticle encapsulated mRNA in prostate cancer patients". aacrjournals.org. Retrieved December 1, 2023.

External links

Add External links

This article "Nutcracker Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.

Retrieved from "https://wikitia.com/index.php?title=Nutcracker_Therapeutics&oldid=196661"